MedAnnex is a privately-owned, preclinical-stage biopharmaceutical company.

Established in 2009 by serial life sciences entrepreneur Professor Chris Wood (Bioenvision, Nucana, Edixomed), we are developing innovative therapies for autoimmune diseases.

Our patent-protected antibody technology has shown significant activity in experimental models of serious autoimmune conditions: rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus (‘lupus’).

Latest News